Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Working with Patients to Design Trials – Our Patient Engagement Network (PEN)

How has a PEN Helped to Design Sjögren's Syndrome Clinical Trials that Embraces the Patient’s Perspective?

What is PEN?

At Bristol Myers Squibb we listen to and try to capture the patient voice as we design our clinical trials. One of the ways we achieve this is to establish a Patient Engagement Network or PEN, which brings together patients, caregivers, clinical site staff and patient advocacy groups together to partner with the BMS clinical study team. We partner with a patient advocacy organization to identify potential patient and caregiver PEN participants that reflect the demographics of a disease. 

In 2015 we established a Sjögren's Syndrome PEN, and here are some of the ways that the PEN has worked with the study team:

In 2015 we established a Sjögren's Syndrome PEN, and here are some of the ways that the PEN has worked with the study team:

  • Reviewing the design of the clinical protocol with the patient in mind
  • Identifying the elements of the protocol that would most likely be barriers to patients and their caregivers
  • Explaining the patient journey to diagnosis so that we can better understand what is needed to make patients and their caregivers aware of the clinical study
  • Advising us on the best communication channels to bring awareness of our studies, so that patients can make informed decisions about joining a clinical trial
  • Helping us design patient facing materials

The insights gained from having a PEN have made a big difference to our approach to our Sjögren's Syndrome studies. As a result of taking the PEN’s suggestions and perspectives on board, we have made revisions to the design of the study and to the way it is being run at our clinical sites.

The patients who are members of the PEN have been very committed to helping other patients with the disease. While PEN members who are patients are not permitted to join the study, they work with us to help ensure that the patient voice is heard so that we can design and run clinical trials that embed the patient and caregiver perspectives. We are grateful for their participation and honored to work with all our PEN members.

Programs like this help us to continuously improve how we conduct research, with the goal of bringing medicines to patients more efficiently and helping to increase patient enrollment and retention in clinical trials.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us